Small and medium-sized pharmaceutical and biotech companies are actively filing applications for drug patents to discover candidate substances and raise their brand recognition.
Access Bio, Cha Biotech, Huons, Medipost, and Genotech obtained medicine-related patients in and out of Korea recently.
Access Bio gained the patent, “A Single-Pad Strip for an Improved Lateral Flow Assay and a Test Device Using the Same,” in the Philippines and Mexico.
The patent is an improved version of the existing immunochromatography technology that can be applied to biochemical reactions. Using a single pad as a strip can shorten the diagnostic time for G6PD (glucose-6-phosphate dehydrogenase) deficiency. The patent allows visual readings of the diagnosis.
The technology also helps measure the activity of enzymes such as glucose-6-phosphate dehydrogenase (G6PD), which allows red blood cells to function properly.
G6PD is a hereditary disease with 400 million patients around the world. If patients with the disease take particular medicines or foods such as antibiotics, antipyretics, and malaria treatment, they can suffer from various side effects such as acute anemia and jaundice due to erythrocyte destruction. There is no treatment for the G6PD deficiency.
Access Bio said its G6PD RDT (Rapid Diagnostic Test) shows diagnostic results within 10 minutes after blood collection, which is highly competitive in the diagnostic market.
Cha Biotech, a unit of Cha Medical Group, has acquired the patent, “Compositions Containing Skin Stem Cell Culture Media for Prevention or Improvement of Skin Ageing,” in Korea.
The patent is a manufacturing method to make cosmetic compositions, which include stem cell-derived skin precursor cell culture fluid, to regenerate skin or prevent skin aging. Cha Biotech aims to utilize the technique to develop and sell related cosmetic products.
The company also obtained the patent, “Isolation and Propagation of Lung Cancer Cells.”
The patent offers a screening of patient-customized cancer treatments, using lung cancer cells extracted from the patient’s lung tissues and proliferated. In developing anti-cancer treatments for lung cancer patients, the company will make use of the patent.
Medipost has seen fruitful results in tackling hair loss. The company recently filed a patent application, “Stem Cell Culture Media’s Promotion of Hair Growth and Its Use.”
The patent is a composition containing stem cell culture fluids, stimulated by hair loss inducing factor, to prevent hair loss and promote hair growth. The company said it would apply the technique to developing a culture fluid treatment for hair loss.
Huons also obtained a patent, “Composition, Containing RGD (arginyl-glycyl-aspartic acid)-containing Peptide or Fragment thereof, for Treating Burns and Glaucoma, Alleviating Skin Wrinkles, and Promoting Hair Growth.”
Genotech applied for a patent in Australia on methods with advantages in test specificity, multi-species SNP (single nucleotide polymorphisms) analysis and mutant genetic testing at no additional cost by utilizing specificity of an enzyme. Genotech said it would use the patent in developing clinical diagnostic products such as genetic disease tests and tumor-related genetic tests.
<© Korea Biomedical Review, All rights reserved.>